The shadow of generic challenges has long loomed around copyright’s famous drug, Sildenafil, sparking questions about the outlook of connected medicinal holdings. While early periods saw substantial profits, the intellectual property lapse has opened the door for discounted copies, potentially diminishing profitability and presenting a genuine ri